REPURPOSING OF AN APPROVED DRUG SPECIFIC FOR VARIOUS NEUROLOGICAL CONDITIONS
Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury.
ASX ANNOUNCEMENTS
VIDEO
Sydney Open Briefing Presentation –
20 November 2019
SUBSCRIBE TO UPDATES
MEDIA
- 10/02/2020 - Rare Disease Day
- 30/01/2020 - Nature Communications: Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics
- 05/12/2019 - Health Kick Podcast: Investing in repurposed drugs, combating intracranial pressure and why Invex caught NASA’s eye
- 21/11/2019 - Q & A with Professor Alexandra Sinclair
- 01/11/2019 - Medical Research That Reaches Outer Space
PARTNERS
CONTACT INFORMATION
Address
Level 1, 38 Rowland St
Subiaco Perth WA 6008
Phone
+61 (08) 6382 0137
ACN 632145334
Disclaimer. Copyright © Invex Therapeutics. All rights reserved. Site developed by NFIC Services.